-
Pharmaceutical stocks have been under the US FDA cloud. Will 2017 fare better? CNBC-TV18's Latha Venkatesh & Sonia Shenoy asks Arpit Vyas, MD of Dishman Pharmaceuticals & Chemicals, Surajit Pal of Prabhudas Lilladher and Vishal Manchanda of Nirmal Bang Institutional Equities.
-
Dishman Pharma‘s all global plants, except China, have been cleared by the US FDA, says JR Vyas, CMD of the company.
-
Two minor observations pertaining to a 2014 audit were reported by the US FDA in its recent inspection, says JR Vyas, CMD of Dishman Pharma.
-
JR Vyas, CMD, Dishman Pharma in an interview to CNBC-TV18 clarified that the company had not received any warning from US FDA on Clovis issue.
-
Talking on their SEZ sale plans he said they would wait for the Budget before deciding on it, said Arpit Vyas, MD, Dishman Pharma.
-
The pharma company is eyeing capex of around Rs 50-60 crore this fiscal year.
-
Dishman Pharma‘s margins were down due to stock building but they are expected to pick up in the second half of this fiscal, says company MD Arpit Vyas.
-
The company is now concentrating on high margins and high value business and expects a sizable improvement by the end of the year.
-
In an interview to CNBC-TV18‘s Anuj Singhal and Sonia Shenoy, Arpit Vyas, Managing Director of Dishman Pharma spoke about the latest happenings in the company and the road ahead.
-
JR Vyas, MD, Dishman Pharma says Carbogen Amcis anticipates a turnover of 96 million this fiscal and a turnover of 106 million the next fiscal year.
-
JR Vyas, CMD, Dishman Pharma said the sale of SEZ land is likely to be concluded in the next fiscal.
-
Arpit Vyas, MD of Dishman Pharma presents his views on the company‘s quarterly earnings, in an interview to CNBC-TV18.
-
The income tax department's surveyed Dishman Pharma's premises over the weekend for taxation issues in a Rs 42 crore land deal involving Dishman SEZ and Dishman Pharma.
-
Arpit Vyas, MD, Dishman Pharma aims at working with EBITDA margins not below USD 25-30 percent and expects to pare down the company debt by Rs 70-80 crore this calendar year.
-
In an interview with CNBC-TV18, JR Vyas, MD of Dishman Pharma said the the contract research income is going to boost the company's performance through FY13.
-
Pharma player Dishman Pharma is looking to cut its debt of Rs 100 crore in FY13. JR Vyas, managing director, Dishman Pharma told CNBC-TV18 that the company would be selling its SEZ land to repay debt.
-
Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.
-
Managing director of Dishman Pharma tells CNBC-TV18 that higher earnings from its contract revenue business is what led to the surge in third quarter profits.
-
Dishman Pharmaceuticals and Chemicals' subsidiary Carbogen Amcis AG has acquired Creapharm Parenterals. In an interview to CNBC-TV18, VVS Murthy, chief financial officer of Dishman Pharma says, it is a small R&D formulation development company. The acquisition, he says, is funded trough internal accruals.
-
Dishman's Managing Director JR Vyas expects its key clients Abbott's contribution to grow by 50%. He further expects some more product orders coming in from Abbott in FY13.
-
Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.
-
In an interview to CNBC-TV18, Dishman Pharma's chief financial officer VVS Murthy said that the change in rupee would not impact the company’s revenues. Murthy projects the company's growth at 15% in FY12.
-
In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.
-
In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma said the company is expecting 15% top-line and bottom-line growth in FY12.
-
VVS Murthy, CFO of Dishman Pharma, in an interview with CNBC-TV18's Latha Venkatesh and Gautam Broker, spoke about the recent report by one of the brokerages Indiabulls Securities, which downgraded the company's stocks and the road ahead.
